熱門資訊> 正文

Kamada的血浆中心获得FDA批准，下一步目标是获得EMA批准

2026-03-26 19:43

Kamada Ltd(KMDA) 0

Kamada (KMDA), a biopharmaceutical company, announced that the FDA has approved its Kamada Plasma collection center in San Antonio, TX, following a February 2026 on-site inspection.
The San Antonio center can support 50 donor beds and, at full capacity, produce up to 50K liters annually.
It also plans to pursue EMA inspection and approval of its San Antonio facility following FDA clearance.
The center could make $8–$10M in annual revenues from normal source plasma at full capacity.

More on Kamada

Kamada's Pipeline And Biosimilars Set Stage For Future Earnings Expansion
Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers
Kamada forecasts double-digit profitable growth in 2026
Seeking Alpha’s Quant Rating on Kamada

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。